NHS Type 2 Diabetes Path to Remission Programme in NENC

Referrer support session

September 19th, 2023



MOMENTA NEWCASTLE

Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps



Background and benefits



Research

- Studies: DiRECT, DROPLET
 - 'Remission' of T2D possible
- Intervention group at 12 mths:
 - 24% lost 15kg+
 - 46% achieved remission (70% retained at 24 mths)
 - Fewer adverse events
- Remission closely linked to weight loss
- Remission: HbA1c
 <48mmol/mol, >6 mths, no meds

Benefits

Patients:

- Weight loss, T2D remission
- Reduction in medications (av. 50%)
- Impact on comorbidities
- Healthy living / Quality of life
- 12 month programme & TDR free
- Participant case studies
- Practices:
 - Free service (NHSE-commissioned)
 - Referrals: WM Enhanced Service
 - Anecdotal: Reduces demands on practice by successful participants (weight loss, impact on comorbidities, peer support). Also medications reviews
 - Extensive support



Framework and Momenta



NHS England approach

- Piloted as NHS Low Calorie
 Diet (2020+) in 20 ICBs
- Similar emerging results to DiRECT
- Now a national Framework (like NDPP):
 - NHS Type 2 Diabetes Path to Remission Programme (T2DR)
 - Design similar to DiRECT
 - Jointly commissioned w' ICB

Momenta Newcastle

- NENC provider: Momenta
- Delivering since 2020
 - Originally: Birmingham & Solihull
 - Now in 7 of 20 T2DR ICBs + others
 - Including South Yorkshire, GM, LLR
- Early outcomes in line with DiRECT / NHSE pilot:
 - 11-13% weight loss at 3 months
 - Maintained into Phase 3
 - Positive uptake (70-80%)
 - Helps address health inequalities



Referral ramp-up required



Current T2DR contract launched as NHS Low Calorie

Diet Programme in Spring 2022

- Phased roll-out
- Recent expansion across NENC (except Newcastle)
- Referrals to 31st January 2024 only
 - Service will continue, new format, provider tbc
- ONLY ~200 of 500 places used to date
- Significant increase required for patients across NENC to benefit from this NHSE-funded resource

NHS

Agenda

- Welcome, questions, recording
- Background and benefits

The programme

- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps



NHS Type 2 Diabetes Path to Remission



- Follows principles of DiRECT, delivered by trained Coaches
- Three phases over 12 months, ALL free to participants:
 - 12 weeks: 8-900 calories/day TDR products
 - 6 weeks: Real food reintroduction
 - 7-8 months: Building healthy eating and activity habits into daily life
 - Plus: TDR Rescue package for those relapsing (>2kg regain)
- Delivery format: In-person groups
- TDR product supplier: Exante
- Coaches: Comprehensive training, nutrition qualification
- 500 'starters' over 2 years to 31 January 2024
 - Service will continue but change format in 2024



Eligibility criteria (summary)



Inclusion

Aged 18-65

- T2D diagnosis within last 6 years
- BMI >=27kg/m² (>=25kg/m² if BAME origin)
- Attended monitoring and diabetes review in last 12 months
- HbA1c within 12 months:
 - If on diabetes medication, HbA1c >=43 mmol/mol (6.1%)
 - If not on diabetes medication, HbA1c >=48 mmol/mol (6.5%)
 - In all cases, HbA1c must be <=87 mmol/mol
 (10.1%)

Exclusion

- Current insulin user
- Currently breastfeeding
- Pregnant or planning pregnancy within 6 mths
- Heart attack or stroke in last 6 months; severe heart failure (New York Heart Association grade 3 or 4); severe renal impairment (most recent eGFR <30mls/min/1.73m2); active liver disease (not including NAFLD); active substance use disorder; active eating disorder; porphyria; or known proliferative retinopathy that has not been treated
- Had bariatric surgery
 - Health professional assessment; or for whom safe and robust medications adjustment is not practical in a primary care setting

NHS Low Calorie Diet Programme Momenta participant journey





Participant experience: Sessions and resources



NHS

MOMENTA NEWCASTLE

Meal replacement products

- ~40+ products (vegan options available)
- Participants order directly (voucher codes provided, support available)
 - Free next-day delivery to home / office
 - Includes 12-week TDR, transition & Reset plan if required
 - Example link: Phase 1 | Exante UK (exantediet.com)
- No cost to participants










Participant resources





• TDR booklet





- Workbook
 - Session overview
 - Content & explanations
 - Activities and quizzes
 - Goals and targets
 - Backup information
 - Safety information



 Trackers e.g. weight, activity, behaviours, specifics



- EXi app (12 mths premium)
- Wallet card
- Pedometer



Agenda



- Welcome, questions, recording
- Background and benefits
- The programme


Roles and responsibilities, referral pathways

- Medications adjustments
- Searches and referrals
- Next steps



NHS T2DR: GP practice & provider responsibilities






Search-based referrals minimise patient travel & waiting times



Identifying interested patients








Patient information



- Patient landing page for invitation texts, social media
 - https://momentanewcastle.com/t2dr-nenc




Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals
- Next steps




Deprescribing: First day of TDR



- Starting medications more familiar than stopping to most
- Comprehensive NHSE Expert Reference Group guidance
 - Safe, evidence-based, pragmatic
 - More conservative than DiRECT
 - Clinical responsibility remains with referring GP
 - Do not replace clinical judgement





MOMENTA NEWCASTLE

Which glucose-lowering agents are safe with TDR?



| Class of medication | Examples of drugs | Is this safe with TDR? |
|------------------------------|---|----------------------------|
| Biguanides | Metformin | Yes – safe |
| Sulfonylureas | Gliclazide, Glibenclamide, Glimepiride | No – risk of hypoglycaemia |
| Meglitinides | Repaglinide, Nateglinide | No – risk of hypoglycaemia |
| Thiazolidinediones | Piogliazone | Yes - safe |
| DPP4 inhibitors (-gliptins) | Linagliptin, Alogliptin, Sitagliptin, Saxagliptin, Vildagliptin | Yes - safe |
| SGLT2 inhibitors (-flozins) | Dapagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin | No – risk of ketoacidosis |
| GLP-1 analogues (-tides) | Exenatide, Dulaglitide, Liraglutide, Lixisenatide, Semaglutide | Yes - safe |
| Alpha-glucosidase inhibitors | Acarbose | Yes – safe |
| | | |

(insulin is not included here as people treated with insulin are not eligible for the NHS LCD Programme pilots)

NHS England and NHS Improvement



Restarting glucose-lowering agents MHS

If Momenta flags that blood glucose is >15, or HbA1c at 6 or 12 months has risen:


- Metformin first line and is also safe in TDR
- Pioglitazone or DPP4 inhibitors are also safe in TDR

Sulfonylureas, meglitinides or SGLT2 inhibitors MUST NOT be used during TDR for safety reasons

If insulin initiation is deemed clinically necessary at any stage patients MUST stop the programme



Adjusting BP-lowering agents




Commence total diet replacement (TDR) products




NFS

Which BP medication to adjust? MHS





Subsequent BP agent adjustment



Blood pressure too high

- SBP 160-179 OR DBP 100-119 : Increase or uptitrate as per NICE Guideline
- SBP ≥180 OR DBP ≥ 120: Same day contact with GP practice. Increase/uptitrate per NICE



 SBP<90 or DBP<60 or postural symptoms reported: Repeat the same process for BP adjustment (on previous slide)

Agents being used specifically and solely for managing BP in a particular patient, are the priority for adjustment



Medications needing adjustment: Weight / dietary changes



Some medications may need to be adjusted due to changes in body weight or dietary intake

Some may be prescribed or administered by other services or settings

Ask yourself 'if someone lost weight or had a major dietary change, is the dose of this medicine likely to need adjustment?'

Responsibility of referrer to make sure that processes are in place for medications to be adjusted

If this cannot be done safely then the patient should not be referred to the T2DR programme



Examples – not exhaustive



- Warfarin
- Direct oral anticoagulants (DOACs)
- Digoxin
- Phenytoin
- Ciclosporin
- Antifungals voriconazole
- Long term antibiotic therapy (e.g. isoniazid) Low molecular weight heparin
- Infliximab (and other biologics)
- Long term antibiotic therapy (e.g. macrolides, aminoglycosides, fluoroquinolones, beta lactams)



Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments

Searches and referrals

Next steps



Making a successful referral



Step 1: Identify & invite eligible patients

Search, screen and invite: searches, template SMS / letter, patient landing page Opportunistically: Discuss at diagnosis, annual review, patient request Bespoke: Patient event

Step 2: Referral appointment, including medications adjustments

Appointment (typically 15 mins): Explain programme and discuss medication changes Make patient aware medication changes to start on day 1 of TDR Provide patient with copy of MAF

Step 3: Send referral

Ensure all sections on referral form and MAF are fully completed and email to:

momenta.nenc-lcd@nhs.net



NHS

Is the patient on the Severe Mental Illness Register? Describe any relevant disability?

This form is for referring eligible patients to the NHS Low Calorie Diet Programme – an in-person group service, delivered by Momenta Newcastle over 12 months, including 12 weeks of 800-900 kcaliday formula diet, aimed at supporting significant weight loss and potential remission of Type 2 diabetes.

Please email completed form to momenta.nenc-lo

| Inclusion criteria | Exclusion criteria |
|--|------------------------------|
| Aged between 18-65 inclusive | Current insulin user |
| Diagnosed with Type 2 diabetes within last 6 years | Currently breastfeeding |
| BMI of >=27kg/m ² (adjusted to >=25kg/m ² in people of | Pregnant or planning to b |
| BAME origin) | months |
| | Note: Weight loss may ca |
| Attended monitoring and diabetes review when last | Has at least one of the fo |
| offered, incl. retinal screening, (or willing to attend | heart attack or stroke in |
| before referral) and commit to continue annual reviews, | York Heart Association gr |
| even if achieve remission | (most recent eGFR <30m |
| HbA1c within 12 months, with values as follows: | gallstones, biliary or liver |
| | substance use disorder; a |
| If on diabetes medication, HbA1c >=43 mmol/mol | proliferative retinopathy |
| (6.1%) | Significant weight loss (> |
| If not on diabetes medication, HbA1c >=48 mmol/mol | currently on a weight ma |
| | Had/awaiting bariatric su |
| (6.5%) | Health professional asses |
| In all cases, HbA1c must be <=87 mmol/mol (10.1%) | understand or meet the |
| | of the NHS LCD Program |
| | appropriate clinically (co |
| | required); or for whom s |
| | not practical in a primary |

Please complete all sections of this form and please ensure eligibility has

| Patient Name*: Mr Tommy Test-TestPatient | | |
|--|--------------------------------|--|
| Sex*: Male | | |
| NHS Number*: | | |
| Address*: 5 Lanchester Road, Durham | | |
| E-mail address: | | |
| Telephone - provide at least one phone number | Home*: | |
| | 0191 334 4557 | |
| Can we leave a voicemail? Yes / No | Does the patient speak English | |
| What is the patient's first language (if not English)? | Does the patient read English | |

| Date of diagnosis of Type 2 diabetes*: | 14 Jul 2021, Typ |
|---|------------------|
| Weight (kg) * must be within last 12 months: | 90 Kg |
| Height (m) *: | 1.8 m |
| BMI (kg/m²) : | |
| HbA1c (mmol/mol) * must be within last 12 months: | |
| Blood pressure (mmHg) *: | 140 / 90 mmHg |
| Is the patient on the Learning Disability Register? | |

| Last issued | Drug name | |
|--|---|--|
| Friday 10 Sep 2021 | Glucosamine sulfate 400mg / Chondroitin su 100mg tablets | |
| Friday 10 Sep 2021 | Gabapentin 100mg capsules | |
| Wednesday 29 Dec 2021 | Sitagliptin 25mg tablets | |
| Wednesday 29 Dec 2021 | Metformin 500mg tablets | |
| Wednesday 29 Dec 2021 | Gliclazide 80mg tablets | |
| televant medication Current diabetes medic | | Dose and |
| | ations Metformin* | Dose and n/a |
| | ations Metformin* Sulfonylureas | Dose and n/a n/a |
| | ations Metformin* Sulfonylureas DPP4 inhibitors (-gliptins) | Dose and n/a n/a n/a |
| | ations Metformin* Sulfonylureas DPP4 inhibitors (-gliptins) SGLT2 inhibitors (-flogios) | Dose and n/a n/a n/a n/a |
| | ations Metformin* Sulfonylureas DPP4 inhibitors (-gliptins) | Dose and n/a n/a n/a |
| | ations Metformin* Sulfonylureas DPP4 inhibitors (-gliptins) SGLT2 inhibitors (-flogios) | Dose and n/a n/a n/a n/a |
| | ations Metformin* Sulfory/ureas DPP4 inhibitors (-gliptins) SGLT2 inhibitors (-flogios) GLP-1 analogues (-tides) | Dose and n/a n/a n/a n/a |
| | ations Metformin* Suffory/ureas DPP4 inhibitors (-gligos) SGLT2 inhibitors (-gligos) GLP-1 analogues (-tides) Pioglitazone | Dose and n/a n/a n/a n/a n/a |
| ürrent diabetes medic | Ations Sufforylureas DPP4 inhibitors (=[gliptins) SGLT2 inhibitors (=[gliptins) GGLP-1 analogues (=tides) Poglitacore Meglitinides (=glinides) | Dose and n/a n/a n/a n/a n/a n/a |
| urrent diabetes medic iny medicines taken w ot taken for BP) | ations Metformin* Sulforn/tureas DPP4 inhibitors (_gliptins) SGIT2 inhibitors (_gliptins) GRP-1 analogues (-tides) Pioglitacone Meglitinides (-glinides) Acarbose | Dose and n/a n/a n/a n/a n/a n/a |

| Declaration* | By entering my name below I confirm th |
|-------------------------|---|
| Declaration* | Meets the inclusion criteria and Understands the context and rr Understands that the NHS LOD that these may be delivered vir Understands that this program with a fibre supplement where Has discussed and agreed their TDR and has been given a writt Agrees that, if they proceed on yearly diabets review appoint remission is achieved, notify th |
| | considered urgent; and notify t end of their intervention; and - Understands and consents to ti |
| Referrer's organisation | Name of GP practice: Dunelm Medical P |

Mr Tommy Test-TestPatient 03 Mar 1967

Referral And Medications Adjustment Form

| NHS |
|-----|
|-----|

Medication Adjustment Form – Low Calorie Diet Programn

Actions required by referring practitioner BEFORE referral

- Complete the form below for all patients. If no me
 Review the patient in a telephone appointment or
- adjustments. Discuss these changes with the patie before they adjust their medications
- Give or send a copy of this Medication Adjustment or not
- 4. Submit the completed Referral and Medication Ad

Instructions for Patient

Registered Practice Code: A83030

GP pract @nh

Referrer's name* Mr Scott

participate in the programme

Their personal and medical info than programme delivery, ensu

The programme is delivered by

an anonymised basis)

test results and outcomes, with safely and evaluated (*some N

Their data will be treated as co

 In the event that a different se referral information will be sha have confidence in their system

Mr Tommy Test-TestPatient 03 Mar 196

the Data Protection Act) and N

Consent: Before referral, confirm the pa • Their personal and medical info

- The table below lists the changes to medications y products on the NHS Low Calorie Diet Programme
- For your safety do not make any changes to your n unless you have been specifically told to do so by y for an updated copy of this form
- 3. Please read this document and keep it safe. You w
- 4. If you have any concerns or questions about this for
- in an appointment (e-consult or telephone would t

| - [| Do any medications need adjusting and, if so, have all changes been noted in the table | Yes / No |
|-----|--|----------|
| | below? (If no, no further action required). * | |
| - [| Have all required medication changes been discussed and agreed with the patient?* | Yes / No |
| | Date form completed : 21 Mar 2022 | |

| Medication Group | Medication Name | Action | Changes to be made ON THE FIRST DAY OF FORMULA DIET PRODUCTS (not before) |
|---|------------------------|--------|--|
| Any other relevant medication requiring adjustment or monitoring | | | |
| Metformin | N/A | N/A | |
| Sulfonylurea | N/A | N/A | |
| DPP4 inhibitor | N/A | N/A | |
| SGLT2 inhibitor | N/A | N/A | |
| GLP-1 | N/A | N/A | |
| Pioglitazone | N/A | N/A | |
| Meglitinide | N/A | N/A | |
| Acarbose | N/A | N/A | |
| Ace inhibitor | N/A | N/A | |
| Angiotensin receptor blocker | N/A | N/A | |
| Calcium channel blocker | N/A Other Drug Name | N/A | |
| Diuretic | N/A Other Drug Name | N/A | |
| Beta-blocker | N/A | N/A | |
| Alpha-blocker | N/A | N/A | |
| Combination Antihypertensive | N/A | N/A | |

Momenta Newcastle will contact your patient within 5 working days of receiving this form.

Mr Tommy Test-TestPatient 03 Mar 1967

Page 5 of 5




Mr Tommy Test-TestPatient 03 Mar 1967

Searches and referral forms: Tips MHS


- Searches
 - Sense check
 - Manual screen to confirm eligibility / appropriateness
 - Historical coding challenges
 - Long lists can be reviewed and invited in batches or triaged
- Referral And Medications Adjustment Form (RAMAF)
 - Confirm eligibility criteria before proceeding
 - Ensure patients receive a copy of the MAF
 - If no medications need adjusting you must still complete the MAF top section (check acutes as well as repeats)
 - We are unable to progress the referral until it is complete and patients recall the information





NHS Type 2 Diabetes Path to Remission Programme pathway: Primary care focus





- <u>Referrer education / drop-in session registration</u>
- Patient landing page: Service overview, eligibility, readiness
- <u>Referrer resources: Eligibility, search, forms, patient info, guidance etc.</u>
- Contact: momenta.nenc-lcd@nhs.net or 01914 814 370
- *SNOMED codes: Momenta will write to practices with all other relevant codes after referral

**The form can be completed by health care professionals other than a GP e.g. practice / diabetes nurses and/or pharmacists as long as the medications adjustments are signed off by a GP or someone they give authority to do so on their behalf.

Agenda



- Welcome, questions, recording
- Background and benefits
- The programme
- Roles and responsibilities, referral pathways
- Medications adjustments
- Searches and referrals

Next steps



Next steps



- Questions / discussion
- Follow-up email and pack
 - Slides, resources, pathway, NHSE guidance, DPIA, recording
- Update colleagues
- Ask us any questions at our weekly Drop-in sessions
- Happy to attend PLT / PCN / other events
- We look forward to your referrals!



Contact details



- Referrals to <u>momenta.nenc-lcd@nhs.net</u>
- Supporting referrals feedback welcome
 - <u>Referrer resources</u>
 - Participant page
- Ongoing support: <u>Register here</u>
 - Drop-ins: 30 mins, any questions Wednesday 1300-1330
- Participant case studies
- Key contacts:
 - ICB: <u>Lynn Sparrey</u>, NENC ICS Diabetes Treatment and Care Project Manager
 - Momenta: Jonny Bruce, Engagement Lead
 - Also Jon Scott, Contract Manager



Thank you for your time Jon Scott jon.scott@momentanewcastle.com

Jonny Bruce jonny.bruce@momentanewcastle.com

MFS



MOMENTA NEWCASTLE